Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling.
Chaohao LiDerek B AllisonDaheng HeFengyi MaoXinyi WangPiotr RychahouIbrahim A ImamYifan KongQiongsi ZhangYanquan ZhangJinghui LiuRuixin WangXiongjian RaoSai WuB Mark EversQing ShaoChi WangZhiguo LiXiaoqi LiuPublished in: PLoS genetics (2023)
Metastasis of lung adenocarcinoma (LUAD) is a major cause of death in patients. Aryl hydrocarbon receptor (AHR), an important transcription factor, is involved in the initiation and progression of lung cancer. Polo-like kinase 1 (PLK1), a serine/threonine kinase, acts as an oncogene promoting the malignancy of multiple cancer types. However, the interaction between these two factors and their significance in lung cancer remain to be determined. In this study, we demonstrate that PLK1 phosphorylates AHR at S489 in LUAD, leading to epithelial-mesenchymal transition (EMT) and metastatic events. RNA-seq analyses reveal that type 2 deiodinase (DIO2) is responsible for EMT and enhanced metastatic potential. DIO2 converts tetraiodothyronine (T4) to triiodothyronine (T3), activating thyroid hormone (TH) signaling. In vitro and in vivo experiments demonstrate that treatment with T3 or T4 promotes the metastasis of LUAD, whereas depletion of DIO2 or a deiodinase inhibitor disrupts this property. Taking together, our results identify the AHR phosphorylation by PLK1 and subsequent activation of DIO2-TH signaling as mechanisms leading to LUAD metastasis. These findings can inform possible therapeutic interventions for this event.
Keyphrases
- epithelial mesenchymal transition
- protein kinase
- rna seq
- single cell
- transcription factor
- small cell lung cancer
- signaling pathway
- squamous cell carcinoma
- end stage renal disease
- transforming growth factor
- newly diagnosed
- ejection fraction
- chronic kidney disease
- papillary thyroid
- physical activity
- gene expression
- peritoneal dialysis
- dna methylation
- dna binding
- combination therapy
- squamous cell
- replacement therapy